Utility‐based outcomes made easy: The number needed per quality‐adjusted life year gained. An observational cohort study of tumor necrosis factor blockade in inflammatory arthritis from Southern Sweden
Objective To introduce a novel, simple, utility‐based outcome measure, the number needed per quality‐adjusted life year (QALY) gained (NNQ), and to apply it in clinical practice in anti–tumor necrosis factor (anti‐TNF)–treated patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and s...
Gespeichert in:
| Veröffentlicht in: | Arthritis care & research (2010) 2010-10, Vol.62 (10), p.1399-1406 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1406 |
|---|---|
| container_issue | 10 |
| container_start_page | 1399 |
| container_title | Arthritis care & research (2010) |
| container_volume | 62 |
| creator | Gülfe, Anders Kristensen, Lars Erik Saxne, Tore Jacobsson, Lennart T. H. Petersson, Ingemar F. Geborek, Pierre |
| description | Objective
To introduce a novel, simple, utility‐based outcome measure, the number needed per quality‐adjusted life year (QALY) gained (NNQ), and to apply it in clinical practice in anti–tumor necrosis factor (anti‐TNF)–treated patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and spondylarthritis (SpA).
Methods
The NNQ is the number of patients one has to treat in order to gain 1 QALY. It is calculated as the inverted value of the utility gain (area under the curve) over 1 year in a cohort subjected to an intervention. EuroQol Index utility data from the South Swedish Arthritis Treatment register were used.
Results
Patients with RA (n = 1,001), PsA (n = 241), and SpA (n = 255) were eligible for the study. First, second, and third treatment courses were studied. For RA, NNQ was 4.5, 6.4, and 5.2 for first, second, and third courses, respectively. For PsA and SpA, NNQ was 4.2–4.5, irrespective of treatment order. Treatment groups with |
| doi_str_mv | 10.1002/acr.20235 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_757178072</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>757178072</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3245-ce6d2b03a0b6da17c3754fac621dfb701e373695f51cd91b49a71a2a78b8e86d3</originalsourceid><addsrcrecordid>eNp1kUtqHDEQhpuQEBvbi1wgaBeymLGkfqgnu2FwHmAw-AHZNSWpOiOnJY0ldUzvcoRcLJfISaLOjL2LEKhUfPXrF39RvGF0ySjl56DCklNe1i-KY85qtqiaun35XFdfj4qzGO9pXiVv23L1ujjitKYN4-y4-H2XzGDS9OfnLwkRNfFjUt5iJBY0EoQ4fSC3WyRutBIDcYg6U7tcPoxwmAR9P8aU24PpkUwIgXwD41AvydoRLyOGH5CMdzAQ5bc-JBLTqCfie5JG62dZFXw0kfSgUr7LwavvswHj8u4HsBZyfyIQ0jaYNJPBW3KT7W4xOHLzmH250-JVD0PEs8N5Utx9vLjdfF5cXn36sllfLlTJq3qhsNFc0hKobDQwoUpRV_nlhjPdS0EZlqJsVnVfM6VXTFYrEAw4iFa22Da6PCne7XV3wT-MGFNnTVQ4DODQj7ETtWCipYJn8v2enP8XA_bdLhgLYeoY7eb8upxf9y-_zL49qI7Son4mn9LKwPkeeDQDTv9X6tab673kXw5fq9E</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>757178072</pqid></control><display><type>article</type><title>Utility‐based outcomes made easy: The number needed per quality‐adjusted life year gained. An observational cohort study of tumor necrosis factor blockade in inflammatory arthritis from Southern Sweden</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Gülfe, Anders ; Kristensen, Lars Erik ; Saxne, Tore ; Jacobsson, Lennart T. H. ; Petersson, Ingemar F. ; Geborek, Pierre</creator><creatorcontrib>Gülfe, Anders ; Kristensen, Lars Erik ; Saxne, Tore ; Jacobsson, Lennart T. H. ; Petersson, Ingemar F. ; Geborek, Pierre</creatorcontrib><description>Objective
To introduce a novel, simple, utility‐based outcome measure, the number needed per quality‐adjusted life year (QALY) gained (NNQ), and to apply it in clinical practice in anti–tumor necrosis factor (anti‐TNF)–treated patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and spondylarthritis (SpA).
Methods
The NNQ is the number of patients one has to treat in order to gain 1 QALY. It is calculated as the inverted value of the utility gain (area under the curve) over 1 year in a cohort subjected to an intervention. EuroQol Index utility data from the South Swedish Arthritis Treatment register were used.
Results
Patients with RA (n = 1,001), PsA (n = 241), and SpA (n = 255) were eligible for the study. First, second, and third treatment courses were studied. For RA, NNQ was 4.5, 6.4, and 5.2 for first, second, and third courses, respectively. For PsA and SpA, NNQ was 4.2–4.5, irrespective of treatment order. Treatment groups with <50 patients were not analyzed. During the study period 2002–2007, there were no secular trends of utility gains.
Conclusion
The NNQ is an easily derived and understandable utility‐based outcome measure that may be useful for stakeholders and decision makers as well as for clinicians. It was readily applied in this study of TNF blockade across 3 arthritis diagnoses. NNQ varied little over diagnoses and treatment course order, with a possible exception in second treatment course in RA.</description><identifier>ISSN: 2151-464X</identifier><identifier>EISSN: 2151-4658</identifier><identifier>DOI: 10.1002/acr.20235</identifier><identifier>PMID: 20506121</identifier><language>eng</language><publisher>Hoboken, USA: John Wiley & Sons, Inc</publisher><subject>Adult ; Antirheumatic Agents - pharmacology ; Antirheumatic Agents - therapeutic use ; Arthritis, Psoriatic - drug therapy ; Arthritis, Psoriatic - epidemiology ; Arthritis, Psoriatic - pathology ; Arthritis, Rheumatoid - drug therapy ; Arthritis, Rheumatoid - epidemiology ; Arthritis, Rheumatoid - pathology ; Biological Products - therapeutic use ; Cohort Studies ; Female ; Humans ; Male ; Middle Aged ; Outcome Assessment (Health Care) - standards ; Quality-Adjusted Life Years ; Spondylarthritis - drug therapy ; Spondylarthritis - epidemiology ; Spondylarthritis - pathology ; Sweden - epidemiology ; Treatment Outcome ; Tumor Necrosis Factor-alpha - antagonists & inhibitors ; Tumor Necrosis Factor-alpha - physiology</subject><ispartof>Arthritis care & research (2010), 2010-10, Vol.62 (10), p.1399-1406</ispartof><rights>Copyright © 2010 by the American College of Rheumatology</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3245-ce6d2b03a0b6da17c3754fac621dfb701e373695f51cd91b49a71a2a78b8e86d3</citedby><cites>FETCH-LOGICAL-c3245-ce6d2b03a0b6da17c3754fac621dfb701e373695f51cd91b49a71a2a78b8e86d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Facr.20235$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Facr.20235$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20506121$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gülfe, Anders</creatorcontrib><creatorcontrib>Kristensen, Lars Erik</creatorcontrib><creatorcontrib>Saxne, Tore</creatorcontrib><creatorcontrib>Jacobsson, Lennart T. H.</creatorcontrib><creatorcontrib>Petersson, Ingemar F.</creatorcontrib><creatorcontrib>Geborek, Pierre</creatorcontrib><title>Utility‐based outcomes made easy: The number needed per quality‐adjusted life year gained. An observational cohort study of tumor necrosis factor blockade in inflammatory arthritis from Southern Sweden</title><title>Arthritis care & research (2010)</title><addtitle>Arthritis Care Res (Hoboken)</addtitle><description>Objective
To introduce a novel, simple, utility‐based outcome measure, the number needed per quality‐adjusted life year (QALY) gained (NNQ), and to apply it in clinical practice in anti–tumor necrosis factor (anti‐TNF)–treated patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and spondylarthritis (SpA).
Methods
The NNQ is the number of patients one has to treat in order to gain 1 QALY. It is calculated as the inverted value of the utility gain (area under the curve) over 1 year in a cohort subjected to an intervention. EuroQol Index utility data from the South Swedish Arthritis Treatment register were used.
Results
Patients with RA (n = 1,001), PsA (n = 241), and SpA (n = 255) were eligible for the study. First, second, and third treatment courses were studied. For RA, NNQ was 4.5, 6.4, and 5.2 for first, second, and third courses, respectively. For PsA and SpA, NNQ was 4.2–4.5, irrespective of treatment order. Treatment groups with <50 patients were not analyzed. During the study period 2002–2007, there were no secular trends of utility gains.
Conclusion
The NNQ is an easily derived and understandable utility‐based outcome measure that may be useful for stakeholders and decision makers as well as for clinicians. It was readily applied in this study of TNF blockade across 3 arthritis diagnoses. NNQ varied little over diagnoses and treatment course order, with a possible exception in second treatment course in RA.</description><subject>Adult</subject><subject>Antirheumatic Agents - pharmacology</subject><subject>Antirheumatic Agents - therapeutic use</subject><subject>Arthritis, Psoriatic - drug therapy</subject><subject>Arthritis, Psoriatic - epidemiology</subject><subject>Arthritis, Psoriatic - pathology</subject><subject>Arthritis, Rheumatoid - drug therapy</subject><subject>Arthritis, Rheumatoid - epidemiology</subject><subject>Arthritis, Rheumatoid - pathology</subject><subject>Biological Products - therapeutic use</subject><subject>Cohort Studies</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Outcome Assessment (Health Care) - standards</subject><subject>Quality-Adjusted Life Years</subject><subject>Spondylarthritis - drug therapy</subject><subject>Spondylarthritis - epidemiology</subject><subject>Spondylarthritis - pathology</subject><subject>Sweden - epidemiology</subject><subject>Treatment Outcome</subject><subject>Tumor Necrosis Factor-alpha - antagonists & inhibitors</subject><subject>Tumor Necrosis Factor-alpha - physiology</subject><issn>2151-464X</issn><issn>2151-4658</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kUtqHDEQhpuQEBvbi1wgaBeymLGkfqgnu2FwHmAw-AHZNSWpOiOnJY0ldUzvcoRcLJfISaLOjL2LEKhUfPXrF39RvGF0ySjl56DCklNe1i-KY85qtqiaun35XFdfj4qzGO9pXiVv23L1ujjitKYN4-y4-H2XzGDS9OfnLwkRNfFjUt5iJBY0EoQ4fSC3WyRutBIDcYg6U7tcPoxwmAR9P8aU24PpkUwIgXwD41AvydoRLyOGH5CMdzAQ5bc-JBLTqCfie5JG62dZFXw0kfSgUr7LwavvswHj8u4HsBZyfyIQ0jaYNJPBW3KT7W4xOHLzmH250-JVD0PEs8N5Utx9vLjdfF5cXn36sllfLlTJq3qhsNFc0hKobDQwoUpRV_nlhjPdS0EZlqJsVnVfM6VXTFYrEAw4iFa22Da6PCne7XV3wT-MGFNnTVQ4DODQj7ETtWCipYJn8v2enP8XA_bdLhgLYeoY7eb8upxf9y-_zL49qI7Son4mn9LKwPkeeDQDTv9X6tab673kXw5fq9E</recordid><startdate>201010</startdate><enddate>201010</enddate><creator>Gülfe, Anders</creator><creator>Kristensen, Lars Erik</creator><creator>Saxne, Tore</creator><creator>Jacobsson, Lennart T. H.</creator><creator>Petersson, Ingemar F.</creator><creator>Geborek, Pierre</creator><general>John Wiley & Sons, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201010</creationdate><title>Utility‐based outcomes made easy: The number needed per quality‐adjusted life year gained. An observational cohort study of tumor necrosis factor blockade in inflammatory arthritis from Southern Sweden</title><author>Gülfe, Anders ; Kristensen, Lars Erik ; Saxne, Tore ; Jacobsson, Lennart T. H. ; Petersson, Ingemar F. ; Geborek, Pierre</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3245-ce6d2b03a0b6da17c3754fac621dfb701e373695f51cd91b49a71a2a78b8e86d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adult</topic><topic>Antirheumatic Agents - pharmacology</topic><topic>Antirheumatic Agents - therapeutic use</topic><topic>Arthritis, Psoriatic - drug therapy</topic><topic>Arthritis, Psoriatic - epidemiology</topic><topic>Arthritis, Psoriatic - pathology</topic><topic>Arthritis, Rheumatoid - drug therapy</topic><topic>Arthritis, Rheumatoid - epidemiology</topic><topic>Arthritis, Rheumatoid - pathology</topic><topic>Biological Products - therapeutic use</topic><topic>Cohort Studies</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Outcome Assessment (Health Care) - standards</topic><topic>Quality-Adjusted Life Years</topic><topic>Spondylarthritis - drug therapy</topic><topic>Spondylarthritis - epidemiology</topic><topic>Spondylarthritis - pathology</topic><topic>Sweden - epidemiology</topic><topic>Treatment Outcome</topic><topic>Tumor Necrosis Factor-alpha - antagonists & inhibitors</topic><topic>Tumor Necrosis Factor-alpha - physiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gülfe, Anders</creatorcontrib><creatorcontrib>Kristensen, Lars Erik</creatorcontrib><creatorcontrib>Saxne, Tore</creatorcontrib><creatorcontrib>Jacobsson, Lennart T. H.</creatorcontrib><creatorcontrib>Petersson, Ingemar F.</creatorcontrib><creatorcontrib>Geborek, Pierre</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Arthritis care & research (2010)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gülfe, Anders</au><au>Kristensen, Lars Erik</au><au>Saxne, Tore</au><au>Jacobsson, Lennart T. H.</au><au>Petersson, Ingemar F.</au><au>Geborek, Pierre</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Utility‐based outcomes made easy: The number needed per quality‐adjusted life year gained. An observational cohort study of tumor necrosis factor blockade in inflammatory arthritis from Southern Sweden</atitle><jtitle>Arthritis care & research (2010)</jtitle><addtitle>Arthritis Care Res (Hoboken)</addtitle><date>2010-10</date><risdate>2010</risdate><volume>62</volume><issue>10</issue><spage>1399</spage><epage>1406</epage><pages>1399-1406</pages><issn>2151-464X</issn><eissn>2151-4658</eissn><abstract>Objective
To introduce a novel, simple, utility‐based outcome measure, the number needed per quality‐adjusted life year (QALY) gained (NNQ), and to apply it in clinical practice in anti–tumor necrosis factor (anti‐TNF)–treated patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and spondylarthritis (SpA).
Methods
The NNQ is the number of patients one has to treat in order to gain 1 QALY. It is calculated as the inverted value of the utility gain (area under the curve) over 1 year in a cohort subjected to an intervention. EuroQol Index utility data from the South Swedish Arthritis Treatment register were used.
Results
Patients with RA (n = 1,001), PsA (n = 241), and SpA (n = 255) were eligible for the study. First, second, and third treatment courses were studied. For RA, NNQ was 4.5, 6.4, and 5.2 for first, second, and third courses, respectively. For PsA and SpA, NNQ was 4.2–4.5, irrespective of treatment order. Treatment groups with <50 patients were not analyzed. During the study period 2002–2007, there were no secular trends of utility gains.
Conclusion
The NNQ is an easily derived and understandable utility‐based outcome measure that may be useful for stakeholders and decision makers as well as for clinicians. It was readily applied in this study of TNF blockade across 3 arthritis diagnoses. NNQ varied little over diagnoses and treatment course order, with a possible exception in second treatment course in RA.</abstract><cop>Hoboken, USA</cop><pub>John Wiley & Sons, Inc</pub><pmid>20506121</pmid><doi>10.1002/acr.20235</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2151-464X |
| ispartof | Arthritis care & research (2010), 2010-10, Vol.62 (10), p.1399-1406 |
| issn | 2151-464X 2151-4658 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_757178072 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adult Antirheumatic Agents - pharmacology Antirheumatic Agents - therapeutic use Arthritis, Psoriatic - drug therapy Arthritis, Psoriatic - epidemiology Arthritis, Psoriatic - pathology Arthritis, Rheumatoid - drug therapy Arthritis, Rheumatoid - epidemiology Arthritis, Rheumatoid - pathology Biological Products - therapeutic use Cohort Studies Female Humans Male Middle Aged Outcome Assessment (Health Care) - standards Quality-Adjusted Life Years Spondylarthritis - drug therapy Spondylarthritis - epidemiology Spondylarthritis - pathology Sweden - epidemiology Treatment Outcome Tumor Necrosis Factor-alpha - antagonists & inhibitors Tumor Necrosis Factor-alpha - physiology |
| title | Utility‐based outcomes made easy: The number needed per quality‐adjusted life year gained. An observational cohort study of tumor necrosis factor blockade in inflammatory arthritis from Southern Sweden |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T20%3A03%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Utility%E2%80%90based%20outcomes%20made%20easy:%20The%20number%20needed%20per%20quality%E2%80%90adjusted%20life%20year%20gained.%20An%20observational%20cohort%20study%20of%20tumor%20necrosis%20factor%20blockade%20in%20inflammatory%20arthritis%20from%20Southern%20Sweden&rft.jtitle=Arthritis%20care%20&%20research%20(2010)&rft.au=G%C3%BClfe,%20Anders&rft.date=2010-10&rft.volume=62&rft.issue=10&rft.spage=1399&rft.epage=1406&rft.pages=1399-1406&rft.issn=2151-464X&rft.eissn=2151-4658&rft_id=info:doi/10.1002/acr.20235&rft_dat=%3Cproquest_cross%3E757178072%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=757178072&rft_id=info:pmid/20506121&rfr_iscdi=true |